🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Study to Evaluate the Efficacy and Safety of DA-9701 in Patients With Functional Dyspepsia

RecruitingPhase 4Ages 19 Years - 75 YearsAllDong-A ST Co., Ltd.
NCT07686679 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study will evaluate the efficacy and safety of DA-9701 in patients with functional dyspepsia

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Main Inclusion Criteria: * Men or women aged 19 to 75 years, inclusive * Subjects diagnosed with functional dyspepsia according to the Rome IV criteria * Subjects with at least three symptoms rated as moderate or severe on the Gastrointestinal Symptom Score(GIS) * Subjects who voluntarily signed a consent form Main Exclusion Criteria: * Subjects with a history of organic diseases that could cause dyspepsia * Subjects with hypersensitivity to investigational drugs and similar drugs * Pregnant or breastfeeding women
💊

What it tests

  • DA-9701
  • DA-9701-R
  • DA-9701 Placebo
  • DA-9701-R Placebo
📍

Where

1 site
Severance Hospital
Seoul, South Korea
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy